Novellus and Tempus Announce Collaboration to Accelerate Clinical Trial Patient Enrollment
Novellus, a clinical-stage biotechnology company focused on precision oncology, and Tempus, a leader in artificial intelligence and precision medicine, announced their collaboration to accelerate patient enrollment for Novellus’ next generation BRAF inhibitor program.
Novellus’ BRAF program focuses on patient populations for which there are currently no FDA-approved BRAF inhibitors, including BRAF fusions and BRAF-mutated gliomas. Novellus will participate in Tempus’s TIME Trial Network, and the companies will work together to identify relevant patients to accelerate patient enrollment.
Recommended AI News: Drone Racing League And Genius Sports Set The Stage For Sports Betting
“The collaboration with Tempus will enable us to accelerate the enrollment of patients in our BRAF trial, by precisely identifying potential candidates and opening sites wherever the patients are found” said Michael Vidne, Chief Executive Officer of Novellus.
Recommended AI News: Black-Owned SaaS Company CredKred Launches To Put Power Of Credit Repair Back In Consumer Hands
“The TIME Trial Program has achieved an unparalleled scale thus far, with over 50 provider networks and 2,500 oncologists included in its network,” said Kim Blackwell, Chief Medical Officer of Tempus. “We’re excited to collaborate with Novellus, to further our mission to increase trial participation, and to ultimately bring the right treatment to the right patients at the right time.”
Recommended AI News: TreasuryXpress Receives The IDC 2020 SaaS TMS Customer Satisfaction Award
Scrap metal residue Ferrous material recycling revenue Iron recycling and reuse
Ferrous material financials, Iron disposal facility, Metal recovery solutions
Copper scrap reclamation techniques Copper recycling partnerships Scrap metal recovery and salvage
Copper cable scrap recovery, Scrap metal reprocessing centers, Copper scrap export market